Inflammatory Bowel Diseases and Parkinson's Disease

Area of Science:

• Neuroscience
• Gastroenterology
• Immunology

Background:

• Parkinson's disease (PD) pathology involves alpha-synuclein aggregation and dopaminergic neuron loss.
• Neuroinflammation, including glial activation and cytokine release, is a recognized feature of PD.
• Emerging evidence implicates gastrointestinal inflammation in PD pathogenesis, potentially preceding motor symptoms.

Purpose of the Study:

• To review the literature on the potential link between inflammatory bowel disease (IBD) and Parkinson's disease (PD).
• To explore the role of gastrointestinal pathology and inflammation in PD development.
• To inform clinicians about the increased PD risk in IBD patients.

Main Methods:

• Literature review of experimental, clinical, and epidemiological data.
• Analysis of genetic association studies between IBD and PD.
• Examination of preclinical models investigating gut inflammation and PD.

Main Results:

• Patients with IBD exhibit a higher risk of developing PD.
• A genetic link between IBD and PD has been identified.
• Animal studies suggest gut inflammation can induce dopaminergic neuron loss and alpha-synuclein aggregation.

Conclusions:

• Gastrointestinal inflammation, particularly in the context of IBD, may significantly contribute to PD pathogenesis.
• Changes in the enteric microbiome and gut infections might trigger PD pathology.
• Clinicians should consider PD symptoms in patients with IBD due to the potential impact of IBD or its treatments on PD risk.